Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

- $161.5 million in cash at year end; no equity financings expected in 2008 - Significant progress in lead lysosomal disease programs to continue in 2008; latest data for all programs to be presented at ACMG meeting in March - Expansion of research and development investment in pharmacological chaperone platform planned for targets beyond lysosomal diseases in 2008

CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally- active pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the fourth quarter and full year of 2007. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.53 per share ($0.48 per share on a non-GAAP basis) for the three months ended December 31, 2007. For the year ended December 31, 2007, on a GAAP basis, the net loss attributable to common stockholders was $3.14 per share ($2.80 per share on a non-GAAP basis). As of December 31, 2007, cash, cash equivalents, and marketable securities totaled $161.5 million. Amicus Chief Financial Officer James Dentzer noted that: "We have ended 2007 in a strong financial position. We have several years of cash on hand, and this is further enhanced by the cost sharing and expected milestones from our partnership with Shire Human Genetic Therapies. As a result, we do not expect to raise cash from any equity financings in 2008."

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, a business unit of Shire plc, to jointly develop Amicus' three lead pharmacological
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Research and Markets has announced the addition ... Report, 2014-2017" report to their offering. ... differentiate into specialized cells and can divide (through mitosis) ... be applied to treatment of cardiovascular diseases, leukemia (a ... or lesion of liver, kidney and other parenchymal organs, ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... a FM-4910 listed material, to stay competitive in ... These high-performance materials ultimately impact product quality ... President and owner. , Established in 1980 in ... strong as many fabricators have left the business. ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
(Date:9/18/2014)... SeqLL Inc., the owner of the ... the closing of a $1M Series-A funding round. ... Technologies, will increase the power of tSMS™ technology ... March 2013 by Daniel Jones, a former Field ... SeqLL has continued to offer Helicos’ sequencing technology, ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... one cell at a ... ... This year marks 10 years of,Guava Technologies bringing sophisticated, yet uniquely ... and clinicians worldwide. Since 1998, the company has,experienced continued success, achieving ...
... WASHINGTON, Feb. 5 Linc Facility Services(R), ... it has acquired Morse Medical,Inc., the largest ... in the Pacific Northwest. The acquisition,is part ... to strengthen its,healthcare service portfolio, and accelerate ...
... N.J., Feb. 5 Memory Pharmaceuticals,Corp. (Nasdaq: ... and Chief,Executive Officer, will provide a company update ... on Tuesday, February 12, 2008 at 10:15 a.m. ... Interested parties may access the live webcast ...
Cached Biology Technology:Guava Technologies Celebrates Tenth Anniversary 2Linc Facility Services Acquires Morse Medical 2
(Date:9/19/2014)... evolve for the sake of fairness per se but ... so say Frans de Waal, PhD, and Sarah Brosnan, ... (IA), which is defined as a negative reaction to ... . , Their conclusion comes after the co-authors ... hypothesis that it is the evolution of forestalling partner ...
(Date:9/18/2014)... researchers have developed a unique method to use microbes ... rural areas. , The first microbe-powered, self-sustaining wastewater ... way to clean up waste from large farming operations ... , Professor Haluk Beyenal and graduate student Timothy Ewing ... the system in the online edition of Journal ...
(Date:9/18/2014)... 2014 New research into the Crimean-Congo hemorrhagic fever ... hemorrhagic disease in humans similar to that caused by ... infection. This discovery has the potential to lead to ... , The research, reported in a paper published ... conducted by scientists at the Texas Biomedical Research Institute ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2
... a group of novel genes that are critical in organ ... the zebrafish secretome. This group of genes makes proteins that ... the body, and are responsible for directing "patterning" in the ... properly form vital organs in the correct places during development. ...
... that animals use song as a way of attracting mates, ... way of scaring off predators ?by singing to them. , ... wild gibbons in Thailand have developed a unique song as ... the gibbons appear to use the song not just to ...
... cells of the testis, providing an explanation for the ... active antiretroviral therapy. The related report by Roulet et ... infection in situ and in vitro,?appears in the December ... According to the most recent World Health Organization data, ...
Cached Biology News:U of MN researchers find novel genes critical in organ development 2Singing for survival 2Singing for survival 3Human testis harbors HIV-1 in resident immune cells 2
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
Printer paper for Model 680 series readers is used with the thermal printers of the Model 680 and Model 680 XR microplate readers. Supplied as 2 rolls....
... with the drug discovery process in mind. ... performance, Safire is the ideal instrument to ... high throughput screening. Safire is a fully ... a range of high speed detection techniques. ...
... cocktail is tailored to efficiently ... suspensions of non-human primate (Rhesus ... using the StemSep (or compatible ... system, achieving a 2.6 Log ...
Biology Products: